Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse - PubMed
5 hours ago
- #measurable residual disease
- #NPM1-mutation
- #acute myeloid leukemia
- The study evaluates real-world outcomes in NPM1-mutated AML, focusing on how measurable residual disease (MRD) influences relapse.
- A post-second cycle chemotherapy MRD cut-off of 0.1% mutNPM1/ABL effectively stratified relapse risk, showing no benefit from allo-SCT in CR1 for patients below this threshold.
- End-of-treatment and follow-up MRD assessments were equally valuable, with high-level MRD (≥0.1%) requiring early intervention to prevent imminent relapse.
- Patients with very low-level MRD (<0.01%) could be safely monitored without further intervention, while those with low-level MRD (≥0.01% and <0.1%) needed close monitoring due to risk of progression.
- The results confirm MRD's prognostic value in bone marrow samples, guiding both transplant decisions and clinical management based on specified thresholds.